Concepedia

Author

Martin Gunnarsson

Örebro University

Also Known As

Anna Fogdell-Hahn, B Astedt, Elizabeth Gray, M Gunnarsson, M. Gunnarsson, Martin Gunnarsson, Mika Gunnarsson

79

Publications

4K

Citations

22

H-Index

38

Concepts

All Affiliations

Örebro UniversityUmeå UniversityKarolinska InstitutetLinköping UniversityUniversity of Gothenburg
MG

About

Martin Gunnarsson is an author at Örebro University specializing in medicine, multiple sclerosis, and clinical trials.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

7

7

588

2

Engineering

1

1

88

3

Natural Sciences

1

1

14

4

Allergy

1

1

17

5

Biochemistry

1

1

14

Martin Gunnarsson

×

39

Publications

3.2K

Citations

21

H-Index

YearCitations

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies

Gustavo Luna, Peter Alping, Joachim Burman,

JAMA Neurology

2019

492

Monitoring disease activity in multiple sclerosis using serum neurofilament light protein

Lenka Novakova, Henrik Zetterberg, Peter Sundström,

Neurology

2017

409

Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab

Martin Gunnarsson, Clas Malmeström, Markus Axelsson,

Annals of Neurology

2010

337

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell,

The Lancet Neurology

2018

327

Neurofilament and glial fibrillary acidic protein in multiple sclerosis

Niklas Norgren, Peter Sundström, Anders Svenningsson,

Neurology

2004

241

Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience

Joachim Burman, Ellen Iacobaeus, Anders Svenningsson,

Journal of Neurology Neurosurgery & Psychiatry

2014

163

Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients

Peter Alping, Johan Askling, Joachim Burman,

Annals of Neurology

2020

130

Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis

Markus Axelsson, Clas Malmeström, Martin Gunnarsson,

Multiple Sclerosis Journal

2013

126

Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial

Anders Svenningsson, Thomas Frisell, Joachim Burman,

The Lancet Neurology

2022

117

Accuracy and reproducibility of a quantitative magnetic resonance imaging method for concurrent measurements of tissue relaxation times and proton density

Wolfgang Krauss, Martin Gunnarsson, Torbjörn Andersson,

Magnetic Resonance Imaging

2015

88

Page 1